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Abstract
Background: There is an ever-growing number of patients requiring aortic valve replacement (AVR). Limited data is
available on the long-term outcomes and structural integrity of bioprosthetic valves in younger patients
undergoing surgical AVR.
Methods: The INSPIRIS RESILIA Durability Registry (INDURE) is a prospective, open-label, multicentre, international
registry with a follow-up of 5 years to assess clinical outcomes of patients younger than 60 years who undergo
surgical AVR using the INSPIRIS RESILIA aortic valve. INDURE will be conducted across 20–22 sites in Europe and
Canada and intends to enrol minimum of 400 patients. Patients will be included if they are scheduled to undergo
AVR with or without concomitant root replacement and/or coronary bypass surgery.
The primary objectives are to 1) determine VARC-2 defined time-related valve safety at one-year (depicted as
freedom from events) and 2) determine freedom from stage 3 structural valve degeneration (SVD) presenting as
morphological abnormalities and severe haemodynamic valve degeneration at 5 years. Secondary objectives
include the assessment of the haemodynamic performance of the valve, all stages of SVD, potential valve-in-valve
procedures, clinical outcomes (in terms of New York Heart Association [NYHA] function class and freedom from
valve-related rehospitalisation) and change in patient quality-of-life.
Discussion: INDURE is a prospective, multicentre registry in Europe and Canada, which will provide much needed
data on the long-term performance of bioprosthetic valves in general and the INSPIRIS RESILIA valve in particular.
The data may help to gather a deeper understanding of the longevity of bioprosthetic valves and may expand the
use of bioprosthetic valves in patients under the age of 60 years.
Trial registration: ClinicalTrials.gov identifier: NCT03666741 (registration received September, 12th, 2018).
Keywords: Aortic valve disease, Surgical aortic valve replacement, SAVR, INSPIRIS RESILIA, Structural valve
degeneration, Valve durability
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Background
There is an ever-growing number of patients requiring
aortic valve replacement (AVR) [1]. The two principal
reasons for AVR are aortic regurgitation (AR) and aortic
stenosis (AS), the latter being the most common indica-
tion. Although the majority of patients is older [2],
younger patients are of particular concern as they have a
longer lifespan with their replaced valve and are
dependent on properly functioning, non-deteriorated
valves over this much longer term.
In general, a wide spectrum of therapies can be offered
to younger patients such as sparing valve techniques and
mechanical valve replacement. Homografts are possible
but less popular due to inferior longevity. The Ross pro-
cedure gains in popularity in selected expert centres.
Mechanical valves have been preferred over biopros-
thetic valves in younger patients, but this is not equivo-
cal. While some studies have shown a survival benefit of
mechanical valves in younger patients [3–7], large retro-
spective observational studies [8–12] and one random-
ized controlled trial [13] have shown similar long-term
survival in patients 50 to 69 years of age undergoing
mechanical versus bioprosthetic valve replacement.
Based on these data, the 2017 American Heart Associ-
ation (AHA)/American College of Cardiology (ACC)
guidelines on valvular heart disease [14] recommend
mechanical over bioprosthetic valves in patients below
the age of 50 years (class IIa, lowered from 60 years in
the 2014 version) and suggest an individualised choice
(so called grey-zone) of either a mechanical or biopros-
thetic valve in patients between 50 and 70 years. Con-
versely, the 2017 European guidelines recommend the
use of mechanical valves in patients under the age of 60
years unless good quality anticoagulation is unlikely and
a grey zone between 60 and 65 years [15]. Both guide-
lines emphasize the need to consider the desire of an in-
formed patient when it comes to the choice of the valve
treatment.
The INSPIRIS RESILIA aortic Valve™ (Edwards Life-
sciences, Irvine, USA) is a stented bioprosthetic, tri-
leaflet valve comprised of bovine pericardial tissue. Spe-
cific new tissue preservation techniques result in a stable
capping process, which blocks residual aldehyde groups
known to bind calcium, in addition to a phospholipid re-
moval process. A final tissue glycerolisation step allows
valve storage without further tissue exposure to glutaral-
dehyde. Finally, INSPIRIS RESILIA features an expan-
sion feature, called VFit, intended for future potential
valve in valve procedures.
RESILIA tissue demonstrated, in a large pre-clinical
randomized control trial conducted in juvenile sheep in
mitral position, to significantly reduce tissue calcification
(− 72%) and even to improve haemodynamic perform-
ance compared with the Perimount valve [16]. The
RESILIA tissue also has been studied in two clinical tri-
als to date [17, 18]. Bartus et al. found, in a single-arm
observational study of 133 patients, that the RESILIA tis-
sue provided excellent performance and safety without
structural valve deterioration (SVD) [18–20]. In the
COMMENCE trial [17, 20], 679 patients underwent
Carpentier-Edwards PERIMOUNT Magna Ease™ aortic
valve replacement with RESILIA™ tissue (Model 11000A)
and similar excellent safety and effectiveness were dem-
onstrated for up to 4 years without SVD. Both of these
trials have included relatively young patients, with a
mean age between 65 and 67 years and up to 26% of pa-
tients aged less than 60 years.
These trials generated useful insights on the safety and
effectiveness of the RESILIA tissue, but they were not
specifically designed to assess durability in younger pa-
tients which received the INSPIRIS RESILIA aortic valve
and data on this topic in general is scarce [21, 22].
It is for this reason that we designed a prospective
long-term registry around the INSPIRIS RESILIA aortic
Valve™. With 400 patients under the age of 60 years in-
cluded and a follow-up of 5 years, we will collect data on
the short-term clinical effectiveness of the valve’s im-
plantation, as well as pivotal data on the long-term
haemodynamic and structural performance of the valve.
Methods/design
The INDURE registry is a prospective, open-label, multi-
centre, international registry with a follow-up of 5 years
to assess the clinical outcomes of patients younger than
60 years of age who undergo surgical AVR with the
INSPIRIS RESILIA aortic valve (Edwards Lifesciences).
The registry is conducted according to ISO 14155:2011.
Approximately 400 patients will be enrolled across 20–
22 European sites (including Austria, Belgium, France,
Germany, Italy, the Netherlands, Spain, and UK) and
Canada, resulting in about 20 patients per site. It was es-
timated, from the COMMENCE Trial dataset [17, 20],
that freedom from time-related valve safety events at 1-
year (composite endpoint according to VARC-2 criteria)
is around 91.5%, suggesting that 400 patients will arrive
at a 95% confidence interval (CI) of ±2.14%. Lower rates
(80%) will broaden the 95% CI to ±3.92% and higher
rates (99%) narrow it down to ±1%.
Patients
Patients under the age of 60 years undergoing SAVR and
receiving the INSPIRIS RESILIA aortic valve prosthesis
will be enrolled on a consecutive basis. In addition to
the applicable criteria of the device Instructions for Use
(IFU), the registry inclusion criteria stipulate that pa-
tients require a planned replacement of their native valve
as indicated in a preoperative evaluation, are scheduled
to undergo planned AVR with or without concomitant
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root replacement and/or coronary bypass surgery. The
latter is understood as isolated AVR with or without
CABG and ascending aortic replacement. Also allowed
is pulmonary vein isolation if it is not a full cox-maze
procedure. Patients with a Bentall procedure or any sur-
gery on other valves are not allowed in this registry. Pa-
tients need to be available to attend yearly follow-up
visits at the registry centre for up to 5 years and all pa-
tients are required to provide written informed consent.
Patients will be excluded from the study if 1) they have
active endocarditis/myocarditis at the time of surgery or
have had it within the last 3 months of the scheduled
SAVR, 2) have had previous AVR, 3) valve implantation
is not possible in accordance with the device IFU, or 4)
they have an estimated life expectancy of less than 12
months for any reason. The intraoperative exclusion cri-
terion is that valve implantation is not possible in ac-
cordance with the device IFU.
Objectives
The primary objectives (Table 1) are to 1) determine the
time-related valve safety at 1-year (composite endpoint
according to the VARC-2 criteria) depicted as freedom
from events [23] and 2) determine freedom from stage 3
SVD following the Salaun definition at 5 years [23, 24].
Events include SVD (either valve-related dysfunction,
defined by haemodynamic parameters or the need for
repeat procedure), prosthetic valve endocarditis, pros-
thetic valve thrombosis, thromboembolic events (e.g.,
stroke) and valve-related bleeding.
The secondary objectives are designed to assess
haemodynamic performance and further durability pa-
rameters, clinical outcomes and quality-of-life (QoL).
The first group of objectives is further defined as the
haemodynamic performance of the INSPIRIS RESILIA
aortic valve including patient prosthesis mismatch
(PPM); SVD following the Salaun definition; and the de-
scription of potential valve-in-valve procedures and clin-
ical outcomes. Clinical outcomes of interest are NYHA
functional class compared to baseline and freedom from
valve-related hospitalisation. Quality-of-life will be
assessed using the Kansas City Cardiomyopathy Ques-
tionnaire (KCCQ) and Short Form-12 Health Survey
(SF-12) [24]. Various additional exploratory analyses re-
garding rehospitalisation, costs and safety will also be
performed.
Data collection
The clinical outcome data collected will be based on the
site’s standard-of-care for surgical AVR. Data will be col-
lected prospectively, according to the timetable set out
in Table 2, and include medical history, physical assess-
ments, electrocardiogram (ECG), laboratory results,
computerised tomography (CT) scans (if performed as a
standard-of-care), transthoracic/transoesophageal echo-
cardiography and QoL measures. Anti-thrombotic ther-
apy and medications are at the discretion of each
investigator. Data will be captured on an electronic case
report form (eCRF) by either a study nurse or physician,
and data will be checked automatically for plausibility
and completeness.
Echocardiography core lab
Digital imaging and communication in medicine
(DICOM) files of echocardiograms generated at years 1
and 5 will be collected for analysis by the Echo Core La-
boratory to ensure unbiased and consistent analysis of
the diagnostic data and, with the use of serial echocar-
diographic studies conducted on the same patient, for
evaluating patient status over the course of 5 years.
Statistical analysis
Continuous variables will be presented as mean ± stand-
ard deviation (SD) or as median with interquartile range
(IQR), and categorical variables (e.g., gender) will be re-
ported as frequencies and percentages. The
Kolmogorov-Smirnov test will be used to test for normal
distribution. Accordingly, the Student t-test or Mann-
Whitney U test will be used to test for statistically sig-
nificant differences. The Chi-Square or Fisher Exact test
will be used for statistical distribution analysis of cat-
egorical variables. Kaplan-Meier analyses will be per-
formed for survival and safety outcomes. Linearized
rates and actuarial probability statistics will be used
where appropriate for adverse event reporting. A P-value
of < 0.05 will be considered statistically significant. Stat-
istical analysis will be performed using SPSS Version
24.0 (Armonk, NY, IBM Corp.).
Discussion
The INDURE registry has been designed to provide pro-
spectively collected data that can be used to elucidate
the benefits and risks of the surgical implantation of
INSPIRIS RESILIA in patients with AVR who are youn-
ger than 60 years of age, as well as the long-term haemo-
dynamic and structural performance of the valve in
patients in this age group. Analysis of the data may also
provide additional support for the earlier use (e.g., at a
younger age) of bioprosthetic valves in patients undergo-
ing AVR.
Bioprosthetic vs. mechanical valves
Mechanical valves are generally preferred over biopros-
thetic valves for younger patients undergoing AVR
because of their perceived greater durability with the 15-
year rates of redo-surgery being 6.9% for mechanical and
12.1% for biological heart valves [10]. It is suggested that
mechanical valves will last throughout the remainder of
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Table 1 Registry objectives
Primary objectives Time-related valve safety at 1 year (composite endpoint according to VARC-2 [23] depicted as freedom from the
following events:
• SVD (valve-related dysfunction [MPG ≥20 mmHg, EOA ≤0.9–1.1 cm2 and/or DVI < 0.35 m/s, AND/OR
moderate or severe prosthetic valve regurgitation], requiring repeat procedure [TAVI or SAVR])
• Valve-related dysfunction
• Requirement of repeat procedures (Re-intervention)
• Prosthetic valve endocarditis
• Prosthetic valve thrombosis
• Thromboembolic events (e.g., stroke)
• Valve-related VARC bleeding
To determine freedom from stage 3 SVD following [24] at 5 years
Secondary objectives Haemodynamics and durability:
• Haemodynamic performance of the INSPIRIS RESILIA Aortic Valve™ including PPM
• SVD following Salaun [24]
• Description of potential ViV procedures and clinical outcome including follow-up
Clinical outcomes:
• NYHA functional class compared to baseline
• Freedom from valve-related rehospitalisation
Quality-of-life:
• 3–6-month, 1-year and 3-year change from baseline in quality-of-life assessed by the KCCQ and SF-12 Health
Survey
Exploratory: Rehospitalisation
and costs
Length of hospital stay
Length of time in intensive care unit
Time to return to work
Rate of valve-related rehospitalisation and associated costs (average costs per country)
Rate of transfusion for bleeding and associated costs (average costs per country)
Costs of a major bleeding event
Costs of daily anticoagulation
Rate of re-intervention for valve degeneration and associated costs (average costs per country)
Exploratory: Safety SVD
Non-SVD
Thromboembolic events (e.g., stroke)
Valve thrombosis
All bleeding/haemorrhage
Major bleeding/haemorrhage
All paravalvular leak
Major paravalvular leak
Endocarditis
All-cause mortality
Cardiac-related mortality
Valve-related mortality
Valve-related re-intervention
Conduction disturbances
Myocardial infarction
Deep sternal wound infection
Acute kidney injury
DVI Doppler velocity index, EOA Effective orifice area, KCCQ Kansas City Cardiomyopathy Questionnaire, MPG Mean pressure gradient, NYHA New York Heart
Association, PPM Patient prosthesis mismatch, SAVR Surgical aortic valve replacement, SF-12 Short Form-12, SVD Structural valve degeneration, TAVI Transcatheter
aortic valve implantation, VARC Valve Academic Research Consortium, ViV Valve-in-valve
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the patient’s lifetime [25]. Mechanical valves do, however,
require daily treatment with anticoagulants, which will in-
crease the risk of bleeding. Lifelong anticoagulation can be
difficult for patients with a history of bleeding issues or an
increased risk of injury related to an active lifestyle. There
may also be dietary restrictions, including reducing the
intake of foods rich in vitamin K when taking vitamin K
antagonists [26]. Newer (or non-vitamin K) oral anticoag-
ulants (NOACs) are strictly contraindicated in patients
with any mechanical prostheses [15, 27, 28]. Next to all
the anticoagulation-related problems, reoperations can be
needed even in mechanical valves in case of pannus over-
growth. Bioprosthetic valves do not require long-term
daily anticoagulants but are at risk of SVD requiring reop-
eration [26]. The risk/benefit profile of mechanical versus
bioprosthetic valves has led to both American and Euro-
pean guidelines on valvular heart disease recommending
the use of mechanical valves in patients younger than 50
years [14, 15] with the European version extending this
recommendation to patients up to 60 years (class IIa, level
C) and the American guidelines considering both mechan-
ical and bioprosthetic valves in patients between 50 and
70 years of age (class IIa, level B, no RCT data). Despite
these recommendations, the use of bioprosthetic valves
has significantly increased over the last few decades across
all age groups [26]. Currently bioprosthetic valves are
being developed that avoid the risk of valve required antic-
oagulation while reducing the reoperation rates seen with
earlier generation bioprosthetic valves.
Determinants and surrogates of valve failure
The ultimate goal when developing durable bioprosthetic
valves, which are particularly required for younger pa-
tients, is to ascertain an uncompromised haemodynamic
function over the very long term with no structural degen-
eration that would otherwise lead to a requirement for
valve replacement or valve-in-valve (ViV) interventions or
death [29, 30]. The data required, however, would take 10,
15 or even 20 years to be collected and assessed and, as
such, shorter-term surrogates of valve degeneration have
been developed which facilitate shorter valve development
cycles. The criteria are plenty, but have been recently
reviewed by different author groups including Capodanno
et al. [31], Dvir et al. [32] and Salaun et al. [24], partly in
an attempt to provide standardised definitions of SVD for
bioprosthetic aortic valves. The definition of SVD by
Salaun [24] (Table 3) has been adopted in the current pro-
ject as it incorporates terminology proposed by both Dvir
[32] and Capodanno [31] and was compatible with the
definition used by Pibarot et al. [34] (see below). We will,
however, capture the components of the other definitions
as well aiming to explore and compare these as well.
Table 2 Data collection schedule
Baseline/screening Surgery Discharge 3–6 monthsa Years 1–5
Signed informed consent X
Medical historyb X
Physical examinationc X X X
ECG (12-lead) X X X
Echocardiogram (TTE) X X X
Core Lab echo Xe
MSCT (if available) Xf
NYHA class/CCS angina class X X X
QoL questionnaire (SF-12 and KCCQ) X X Xg
Anti-thromboembolic therapy and medications X X X X
Procedural information X
Aetiology X
SAE reporting X X X X
Discharge data X
Rehospitalisation datad X X
Return to work X X
CCS Canadian Cardiovascular Society, ECG Electrocardiogram, KCCQ Kansas City Cardiomyopathy Questionnaire, MSCT Multi-slice computed tomography, NYHA
New York Heart Association, QoL Quality of life, SAE Serious adverse event(s), SF-12 Short Form-12 Health Survey, TTE Transthoracic echocardiogram
aData captured over a telephone call
bIncludes cardiovascular and non-cardiovascular conditions, prior cardiac interventions and surgeries
cPhysical examination, includes height, weight and vital signs (blood pressure and heart rate)
dIncludes re-interventions, potential valve-to-valve procedures, associated costs
eSolely performed at 1-year and 5-years of follow-up
fSolely documented at 5-years of follow-up
gSolely performed at baseline, 3–6 months and years 1 and 3 of follow-up
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INDURE in perspective
The RESILIA tissue has been studied in two trials to date
[17, 18] with a total of 812 patients showing that its use
results in excellent haemodynamic performance and safety
up to 2 years. Both the RESILIENCE trial [34] and the
INDURE registry were set up in order to assess the long-
term performance and structural integrity of bioprosthetic
valves using the RESILIA tissue in younger patients. RESI-
LIA tissue incorporates an anti-calcification process, by
permanently blocking the residual aldehyde groups that
Table 3 Definition of structural valve deterioration of aortic bioprostheses following Salaun [24]
Stage 0a
No SVD
Stage 1a
SVD with no HVD
‘Morphological
SVD’b
Stage 2a
SVD with moderate HVD
‘moderate hemodynamic
SVD’b
Stage 3a
SVD with severe HVD
‘Severe hemodynamic
SVD’b
Valve leaflet morphology and motion by TTE, TEE or MDCT
Leaflet morphology
Valve leaflet thickening:
At least one leaflet with thickness≥ 2 mm
Absent Present Present Present
Valve leaflet fibrocalcific remodelling:
Hyper echogenicity (TTE/TEE) or hyper density
(MDCT)
Detectable leaflet calcification at MDCT
Absent Present Present Present
Leaflet motion
Reduced mobility Absent Absent or mild Mild to moderate Moderate to severe
Leaflet tear/avulsion Absent Absent May be present May be present
Valve haemodynamics by TTE
Mean transprosthetic gradient
Absolute increase from baselinec < 10 mmHg < 10mmHg 10–19 mmHg ≥20mmHg
Mean gradient at post-AVR echod < 20 mmHg < 20mmHg 20–39 mmHg ≥40mmHg
Valve effective orifice area
Absolute decrease from baseline < 0.30 cm2 < 0.30 cm2 0.30–0.59 cm2 ≥0.60 cm2
Doppler velocity index
Absolute decrease from baseline < 0.1 < 0.1 0.1–0.2 ≥0.2
Transprosthetic valve regurgitationc
Worsening compared with baseline Absent None ≥1 Grade ≥2 Grades
Grade of regurgitation None, trace or
mild
None, trace or
mild
Moderate Severe
Clinical status Subclinical Often subclinical Generally clinically
expressive
New onset or worsening symptoms Absent Often absent Generally present
New onset or worsening LV dilation/hypertrophy/
dysfunction
Absent Generally absent Often present
New onset or worsening pulmonary hypertension Absent Generally absent Often present
The classification and criteria presented in this table are based on recommendations and standardised definitions of medical societies or group of experts [31–33]
Stage 0 refers to a normal valve. Stage 1 consists in the presence of morphological abnormalities of valve leaflets but with no evidence of HVD. At
echocardiography, the leaflets are thickened (> 2 mm), often irregular and hyperechogenic. MDCT without contrast may be used to detect and quantitate
macroscopic valve leaflet calcification by the modified Agatston method or the volumetric method. Stage 2 consists in SVD with moderate HVD defined as: (1) an
increase in mean transprosthetic gradient ≥10 mmHg since early post-SAVR or TAVI echocardiography with concomitant decrease in valve EOA and DVI; and/or (2)
a new onset or worsening of transprosthetic regurgitation by at least one grade with a final grade of moderate. An increase in transprosthetic velocity and
gradients with concomitant increase in valve EOA and DVI is actually related to an increase in flow during follow-up and should not be mistaken for an HVD.
Stage 3 consists in SVD with severe HVD characterised by: (1) an increase in mean transprosthetic gradient ≥20 mmHg since SAVR or TAVI with concomitant
marked decrease in valve EOA and DVI and/or (2) new onset or worsening of transprosthetic regurgitation by at least two grades with final grade of
severe regurgitation
AVR Aortic valve replacement, DVI Doppler velocity index, EOA Effective orifice area, HVD Haemodynamic valve deterioration, LV Left ventricle, MDCT Multidetector
CT, SVD Structural valve deterioration, SAVR Surgical aortic valve replacement, TAVI Transcatheter aortic valve implantation, TEE Transesophageal
echocardiography, TTE Transthoracic echocardiography
Classification terminology proposed by: aDvir et al. [32] and bCapodanno et al. [31]
cThe most important criteria to define haemodynamic HVD is a significant increase in mean transprosthetic gradient with concomitant decrease in valve EOA and
DVI; and/or a new onset or a worsening of transprosthetic valve regurgitation
dThis criterium is corroborative but should not be used in isolation to define HVD
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are known to bind calcium. Calcification is known to
occur more commonly on bioprosthetic valves than mech-
anical valves [35]. It, therefore, has the potential to in-
crease valve longevity and consequently reduce re-
intervention rates.
Both INDURE and RESILIENCE (Table 4) are pro-
spective studies, including patients with either the
INSPIRIS RESILIA valve (INDURE) or any RESILIA tis-
sue bearing valve (RESILIENCE). While INDURE will
follow patients from the time of surgery for 5 years, RE-
SILIENCE pursues retrospective inclusion of patients
with the first visit being 5-years after surgical interven-
tion and a prospective follow-up (up to year 11 after the
implant). On the one hand, INDURE puts emphasis on a
combination of time-related valve safety at 1-year, SVD
defined according to Salaun [24] using a CoreLab and
clinical outcomes, while on the other hand RESILIENCE
focuses on the multi-slice computed tomography
(MSCT) and echo-based (both CoreLab) prediction of
re-intervention or valve-related death. Projected comple-
tion dates are 2025 (INDURE) and 2027 (RESILIENCE),
respectively.
Up and beyond INDURE and RESILIENCE there is a
third long-term data collection ongoing (IMPACT;
NCT04053088) using the INSPIRIS RESILIA valve. It is be-
ing conducted in Germany, Austria, Switzerland and The
Netherlands and will follow up to 500 patients for 5 years.
The principal objective of IMPACT is the assessment of
the impact of comorbidities such as chronic kidney disease
(CKD), diabetes, hypertension, metabolic syndrome and in-
flammation on all-cause mortality. Among the secondary
objectives there is, again, assessment of SVD, which will
complement the data derived from INDURE and
RESILIENCE.
Appreciation of the study design
The INDURE registry is a prospective, open-label, multi-
centre, international registry. The multinational nature
of this registry increases the applicability of findings to
clinical practice all over Europe and Canada. However, it
has no control group making a comparison of different
bioprosthetic valves or valve generations impossible.
Furthermore, there is no comparison of the biopros-
thetic valve data with the outcomes of mechanical valve
implantation, which would be desirable, but goes beyond
the possibilities of such a project. Because of the multi-
centre design, an Echo CoreLab has been established to
have a uniform assessment of SVD over the time course
of the 5-year follow-up. We considered establishing an
MSCT CoreLab, as has been incorporated in the RESILI-
ENCE trial, but it would have violated the non-
interventional nature of the INDURE registry as most
sites reported that an MSCT is not standard-of-care at
their institution, which may be considered as a limita-
tion. Nonetheless these data can be documented in case
they are available from routine practice. Finally, the
same INSPIRIS RESILIA valve will be used in all patients
in the INDURE registry which will abolish any bias in-
troduced by the use of different bioprosthetic valves.
Conclusions
INDURE is a prospective, multicentre registry in Europe
and Canada that will provide much needed data on the
long-term durability of bioprosthetic valves in general
Table 4 INDURE vs. RESILIENCE
INDURE (NCT03666741) RESILIENCE (NCT03680040)
Valve used INSPIRIS valves RESILIA tissue valves
Design Prospective Retrospective inclusion, prospective follow-up
Study Start
date
26 April 2019 5 November 2018
Baseline Implantation 5 years
Follow-up 5 years – projected completion 2025 6 years (from year 5 to year 11) – projected completion 2027
Subjects/
centres
400 subjects, 20–25 centres (EU and Canada) under the
age of 60 years at the time of their SAVR
220 subjects, up to 15 centres (US and EU) under the age of 65 years at
the time of their SAVR
Objective Assess clinical outcomes Time to valve failure due to valve degeneration requiring re-intervention &
early potential predictors of valve durability
Primary
endpoints
Time-related valve safety at 1 year (VARC-2) Time to BVF due to SVD, defined as requiring re-intervention (redo surgery
or ViV), or confirmed valve related death, according to Akin criteria [29]
Rate of severe SVD (stage 3 following Salaun [24]) at 5
years (Echo CoreLab)
Secondary
endpoints
Haemodynamics and durability (Echo CoreLab)
Clinical outcomes (NYHA and freedom from
rehospitalisation)
Quality-of-life (KCCQ & SF-12)
Early possible predictors of valve failure including leaflet calcification and
morphological/haemodynamic valve degeneration:
-Valve leaflet calcification via CoreLab evaluated MSCT (no contrast)
-Haemodynamic performance (Echo CoreLab)
BVF Bioprosthetic valve failure, EU European Union, KCCQ Kansas City Cardiomyopathy Questionnaire, MSCT Multi-slice computed tomography, NYHA New York
Heart Association, SF-12 Short Form-12, SVD Structural valve degeneration, US United States, VARC Valve Academic Research Consortium, ViV Valve-in-valve
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and the INSPIRIS RESILIA valve in particular. The data
may help to gather a deeper understanding of the longevity
of bioprosthetic valves and may expand the use of biopros-
thetic valves in patients under the age of 50 and 60 years.
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